Cargando…
Peroxisome proliferator-activated receptor gamma as a therapeutic target for hepatocellular carcinoma: Experimental and clinical scenarios
Hepatocellular carcinoma (HCC) is the most common type of liver cancer worldwide. Viral hepatitis is a significant risk factor for HCC, although metabolic syndrome and diabetes are more frequently associated with the HCC. With increasing prevalence, there is expected to be > 1 million cases annua...
Autores principales: | Katoch, Swati, Sharma, Vinesh, Patial, Vikram |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9372809/ https://www.ncbi.nlm.nih.gov/pubmed/36161051 http://dx.doi.org/10.3748/wjg.v28.i28.3535 |
Ejemplares similares
-
Peroxisome proliferator-activated receptor gamma and its natural agonists in the treatment of kidney diseases
por: Sharma, Vinesh, et al.
Publicado: (2022) -
Emerging role of the peroxisome proliferator-activated receptor-gamma in hepatocellular carcinoma
por: Hsu, Hui-Tzu, et al.
Publicado: (2014) -
Prognostic and immunological significance of peroxisome proliferator-activated receptor gamma in hepatocellular carcinoma based on multiple databases
por: Wang, Chaoban, et al.
Publicado: (2022) -
Gut Microbiota, Peroxisome Proliferator-Activated Receptors, and Hepatocellular Carcinoma
por: Yu, Qiang, et al.
Publicado: (2020) -
Peroxisome Proliferator Activated Receptor Gamma Sensitizes Non-small Cell Lung Carcinoma to Gamma Irradiation Induced Apoptosis
por: Kaur, Simran, et al.
Publicado: (2019)